Business Context and Reporting Period
This Form 8-K is a Current Report filed by PharmAthene, Inc. (not Altimmune, Inc.) on April 28, 2009. The filing serves as a Regulation FD disclosure to announce an upcoming investor conference call regarding the company's rPA anthrax vaccine program (SparVax®).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly an announcement of a corporate event.
Material Changes
No material financial changes or operational results are reported in this filing. The primary update is the scheduling of a conference call to discuss:
- The overall status of the SparVax® program.
- Existing funding for the program.
- The status of the company's bid under the DHHS Request for Proposal (RFP-BARDA-08-15) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile.
Guidance, Outlook, and Management Commentary
Management has scheduled a conference call for Wednesday, April 29, 2009, at 4:30 p.m. E.T. to provide updates on the items listed above. The call will be webcast on the company's website, and a replay will be available for 30 days. The company intends to furnish the transcript of this call as an exhibit to a subsequent Form 8-K.
Investor Verification Checklist
- Verify the company name is PharmAthene, Inc., as the input metadata referenced Altimmune, Inc.
- Confirm the outcome of the DHHS RFP-BARDA-08-15 bid by listening to the conference call or reviewing the subsequent transcript.
- Review the company's most recent 10-Q or 10-K for actual financial metrics, as this 8-K contains none.
- Monitor the Strategic National Stockpile contract award status for the rPA vaccine.